Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weifuchun in gastric precancerous lesions (JAK2/STAT3 pathway)
ChiCTR2200061717Phase 4Not yet recruiting
- Sponsor
- Zhejiang Medical Association
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of weifuchun in chronic non-atrophic gastritis, atrophic gastritis (AG), Intestinal metaplasia and 1 more (4 arms), sponsored by Zhejiang Medical Association. Primary endpoints: Positive expression rate of JAK2, Positive expression rate of STAT3 and 1 more. Planned start Jul 2022; status: not yet recruiting.
02
Drugs
weifuchun
03
Conditions
chronic non-atrophic gastritisatrophic gastritis (AG)Intestinal metaplasiagastric dysplasia
Beyond the preview
Go deeper on ChiCTR2200061717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200061717.